about
Role of cytochrome P450 in drug interactionsRisk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and societyHuman cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10Pharmacogenetics and pharmacogenomicsMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsMolecular genetics of the human cytochrome P450 monooxygenase superfamilyEffects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitroInterindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetaminePharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteersImpaired oxidation of debrisoquine in patients with perhexiline neuropathyPharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquineDisposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6.Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing.Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphismChromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylaseOxidative polymorphism of debrisoquine in Parkinson's diseaseClinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugsOcular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers.A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Clinically significant pharmacokinetic drug interactions between antiepileptic drugs.The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.Polymorphic hydroxylation of perhexiline maleate in man.The genetic control of phenformin 4-hydroxylation.Gender-related differences in pharmacokinetics and their clinical significance.Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy.Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.Pharmacogenomics: the genomics of drug response.Xenobiotic metabolism, genetic polymorphisms and male infertility.Ethnic differences in drug metabolism.Pharmacogenomics: a systems approach.Implementation and utilization of genetic testing in personalized medicine.Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trialsPharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
P2860
Q21245066-C5B10B86-DACD-4773-A284-1B45048BD655Q24289220-C9EED4D8-9863-424A-8229-B2CA8FA71A23Q24339638-397B10FE-E4A7-4D18-ACFC-ADFF3AD4BC81Q24564983-3B97202D-0309-4754-90E0-13987FABFEF1Q24683013-0C8DA020-C203-4152-A130-403F8CC86906Q26787099-5955B7DF-D0CD-4CAC-AAB3-28E392EC1A76Q28293994-51E62D83-FD5F-4242-A777-97B06A132805Q28295439-C756C440-9548-4B8B-A07C-8933FEE10471Q28330718-FC5A648B-9854-4349-B8B6-34E07F4B0A41Q28361024-4153FA4D-2D07-4FB4-BBDD-BD52E2E4A56AQ28366143-9E0A65C2-EE32-4ABC-AAE8-A9369C097F84Q28609389-74279C7A-48F6-4FE0-86AB-6388960FB778Q28609390-5C29244F-1899-448B-BC5E-9A36E99EFCC8Q30711413-3A47216F-2D4E-44A5-B39D-AFD386A2538CQ30976703-2867086C-5ED6-4900-B520-1A066DE623C3Q31144283-DD0D29EB-4D1B-47DF-BCD0-252CE5373680Q33245041-E434498B-3579-499C-AC8F-0BFF516E01F0Q33567320-31E8BBEF-1D86-42AE-8196-2695B001F3A9Q33588811-908858D7-C93F-4FC2-A1B3-F126921B5823Q33630990-A4DE40E0-AA54-4057-AE28-39454C8772ACQ33632924-49904DD3-30ED-4A77-8CF4-787F4A29B9CEQ33646125-21061FA3-F774-43BA-A1F5-B1706C8ECDE5Q33667784-8B4DBD89-B9F8-4688-93E9-5066FC30DEC9Q33668831-DB677418-78D9-4119-B8C6-B4553548588DQ33670797-7773AABA-CC95-4DEE-8054-DE21A952F709Q33671047-858B7F52-A5C5-43FB-BD4F-DF40254866DCQ33672163-B50DA58F-79ED-4CF9-9046-1BACA86A2062Q33785861-4CCE1308-684E-4A21-83BF-C60CFC587D92Q33826374-C53B832F-C943-42AD-8FC1-84032C39BF5FQ33899650-5084A680-168B-4EE1-86CF-E02C99CCCF4BQ33910630-CD697844-AE06-403E-948F-C6EF5126E1C0Q34054703-32E4B622-07A8-4618-943F-04CF1F24D97BQ34093123-9E1B0804-4021-4EBB-86BD-1C1E938B55BFQ34137575-EFB125AC-0F1C-41D9-B31F-D9C6BAEB06A3Q34147916-1485C1CF-761C-4143-A957-CDDD4A38C019Q34180464-316D1C98-7637-4C2C-941B-0A409B37F902Q34188511-20C9F3B9-3AA1-4F86-A28A-3D4C2E13EEC9Q34273354-449ADD8D-8B25-479C-B9C1-66E37295072BQ34331552-59053A1C-F74F-497F-B40D-0EFA713549E9Q34345969-B33297C1-2A88-499B-A901-A70C264E3FD6
P2860
description
1977 nî lūn-bûn
@nan
1977 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Polymorphic hydroxylation of Debrisoquine in man.
@ast
Polymorphic hydroxylation of Debrisoquine in man.
@en
Polymorphic hydroxylation of Debrisoquine in man.
@nl
type
label
Polymorphic hydroxylation of Debrisoquine in man.
@ast
Polymorphic hydroxylation of Debrisoquine in man.
@en
Polymorphic hydroxylation of Debrisoquine in man.
@nl
prefLabel
Polymorphic hydroxylation of Debrisoquine in man.
@ast
Polymorphic hydroxylation of Debrisoquine in man.
@en
Polymorphic hydroxylation of Debrisoquine in man.
@nl
P2093
P1433
P1476
Polymorphic hydroxylation of Debrisoquine in man.
@en
P2093
P304
P356
10.1016/S0140-6736(77)91430-1
P407
P577
1977-09-01T00:00:00Z